Publication for Ldlr and Scd1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
mmu	Ldlr	low density lipoprotein receptor	16835			[link]
mmu	Scd1	stearoyl-Coenzyme A desaturase 1	20249

Pubmed ID	Priority	Text
25147951	0.98	Scd1, Sc4mol, Fads2, Scd2, Stard4, Ldlr, Insig-1, and Fdps, which are direct targets of SREBPs and involved in the cholesterol/lipid biosynthetic pathways, are down-regulated in S1Pcko cartilage (Table 2) mirroring that seen in the microarray.
	0.97	Scd1, Scd2, Ldlr, Fads2, and Fdps genes at the RNA level in the humerus of S1Pcko mice (Fig. 8).
	0.93	Scd1, Scd2, Ldlr, Fads2, and Fdps genes at the RNA level, shown by in situ hybridization in S1Pcko humerus and by immunohistochemistry (IHC) for Scd1 protein in S1Pcko femur.
26619823	0.98	stearoyl-CoA desaturase-1 (Scd1) showed a tendency to increase in the livers of LD-fed Elovl6-/-Ldlr-/- mice compared with LD-fed Elovl6+/+Ldlr-/- mice (Fig. 6A).
26074075	0.97	Ldlr-/- mice, consistent with a protective function of Scd1 against plaque formation, and in line with the anti-atherogenic function of Dbc1 deficiency in ApoE-/- mice.
	0.96	Ldlr-/- double knockouts fed a western-type diet (WTD), we confirmed the increase of Scd1 (Figures S4A and S4B) as well as a constellation of atherogenic findings, including increased body weight, hepatosteatosis, dyslipidemia, and insulin resistance (Table S1).
24438079	0.97	stearoyl-CoA desaturase 1 (SCD1; Scd1) were elevated in HFSC- compared to HFC-fed LDLR-/- mice after 16 weeks of treatment (Figure 5A-C).
25155036	0.97	LDLR, SCD-1, and DGAT-2 are all targets of SREBP-1c.
32176696	0.97	Scd1 in on a Ldlr-/- background resulted in an altered plasma lipid pattern.
27499577	0.96	SCD-1, FAS, LDLR, and CYP7alpha1 in the liver.
	0.96	SCD-1, FAS, HMGCR, LDLR, CYP7alpha1 and PPAR-alpha proteins in the liver; and the SREBP-1, SCD-1, FAS, PPAR-alpha and adiponectin proteins in adipose tissue were reversed by PGBR.
	0.96	SCD-1, FAS, LDLR and CYP7alpha1 were enhanced by HFD.
	0.95	SCD-1 (130%), FAS (320%), LDLR (31%) and CYP7alpha1 (74%) proteins, compared with the SRD group.
	0.94	SCD-1 (34%), FAS (57%), HMGCR (78%), and increase in LDLR (50%), CYP7alpha1 (66%) and PPARalpha (75%) protein levels compared with the HFD group (Fig. 1).
	0.92	SCD-1, FAS, HMGCR, increasing LDLR, CYP7alpha1 and recovering adiponectin through regulating PPARs.
	0.92	SCD-1, FAS, HMGCR, LDLR, CYP7alpha1, PPARalpha, and adiponectin in liver and adipose tissue were recovered by PGBR.
	0.89	SCD-1, FAS, HMGCR, LDLR, CYP7alpha1 and PPARalpha protein expressions in liver of high-fat diet (HFD) fed mice.
18794388	0.96	SCD1 inhibition promotes SFA- and cholesterol-rich atherosclerotic lesion formation in LDLr-/-Apob100/100 mice.
	0.93	SCD1 inhibition promotes atherosclerosis in LDLr-/-Apob100/100 mice.
	0.90	SCD1 inhibition prevents diet-induced obesity and insulin resistance in LDLr-/- Apob100/100 mice.
	0.89	SCD1 inhibition prevented diet-induced obesity in LDLr-/-Apob100/100 mice.
20216310	0.96	SCD1 lowers HDL-C levels in LDLr-/-, apoB100/100 mice.
	0.91	SCD1 mutant), and in hyperlipidemic mice lacking the low-density lipoprotein receptor (LDLr-/-).
27050512	0.96	LDLR and other lipogenic enzymes (e.g., SCD1 and FASN) play an important role in tumorigenesis.
28030540	0.95	Ldlr-/- showed significantly higher mRNA levels for PPARgamma and stearoyl-coenzyme A desaturase 1 compared to wild-type animals (Table 4).
29463801	0.95	SCD-1 KO mice displayed decreased FASN, LDLR and UCP-1 expression compared to wild-type.
19910642	0.94	SCD1-/- mice in our study, a recent study using a SCD1-/-:LDLR-/- mouse model showed that SCD1 deficiency resulted in increased atherosclerosis.
	0.84	SCD1-/-:LDLR-/- mice in that study, the levels of MCP-1 that is highly produced by WAT were actually lower in these mice.
	0.75	SCD1-/-:LDLR-/- mouse model.
29965978	0.94	SCD1 knock-out mice that were crossed with low density lipoprotein receptor (LDLR)-deficient mice displayed increased atherosclerosis.
	0.69	LDLR-deficient mouse, to determine if SCD1 deletion in the skin offers protection from developing atherosclerotic lesions.
23580231	0.94	Low Density Lipoprotein Receptor (LDLR), HMG-CoA reductase, and PCSK9, remained unchanged by mRNA-seq and qPCR, though SCD1 was decreased by ~50% in Sec24agt/gt mice (Figure 5D), as observed by mRNA-seq (FDR < 3 x 10-13).
29051579	0.94	SCD1 in LDLR-/- mice.
19834103	0.93	SCD1 ASO synergistically improves hyperlipidemia in LDLr-/-, ApoB100/100 mice.
	0.88	SCD1 ASO-driven atherosclerosis in LDLr-/-, ApoB100/100 mice.
26061913	0.93	SCD-1 accelerates atherogenesis in LDLR-deficient mice.
23285120	0.91	stearoyl CoA desaturase-1 (SCD1) expression is down-regulated by CLA supplementation, we found that each of the individual isomers as well as the CLA Mix increased SCD1 mRNA in the LDLr-/- animals, although the changes were not significantly different from the HFC (data not shown).
32027669	0.90	Scd1), but also direct cholesterol transport (Ldlr, Pcsk9, Stard4) and retinoid synthesis (Aldh1a1, Rdh11).
19014463	0.79	Stearoyl CoA desaturase 1, cholesterol synthesis and uptake genes, HMG CoA reductase, LDL receptor and Egr-1 transcription factor gene, that are also activated by IGF-1 in this study.